ArticleThe European respiratory journal2024
Mortality trends in idiopathic pulmonary fibrosis in Europe between 2013 and 2018.
Article in The European respiratory journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Psychometric properties of health-related quality of life assessment instruments in idiopathic pulmonary fibrosis: a systematic review applying COSMIN methodology.Health and quality of life outcomes · 2026Pooled it
- MicroRNA regulation in pulmonary fibrosis: a bibliometric analysis of global research trends, collaborative networks, and emerging frontiers.Frontiers in medicine · 2026Pooled it
- TRPML1 agonist ML-SA5 attenuates pulmonary fibroblast activation by suppressing mTOR and restoring autophagic flux.FEBS open bio · 2026Article
- Comorbidity in Patients with Idiopathic Pulmonary Fibrosis: Evaluation Using the Charlson, TORVAN and GAP Indices.Journal of clinical medicine · 2026Article
- Trends in mortality due to GPA/MPA across Europe: insights from a decade of death registrations.Rheumatology (Oxford, England) · 2026Article
- National and provincial burden of interstitial lung disease mortality in China, 2013-2021: a nationwide analysis of trends and underlying cause of death.Respiratory research · 2026Article
- Mortality trends in chronic obstructive pulmonary disease in 27 countries within Europe from 2011 to 2021.BMJ open respiratory research · 2026Article
- Inefficacy of dexamethasone and pirfenidone as comparators in the bleomycin-induced pulmonary fibrosis model in SD rats.Frontiers in medicine · 2026Article
- Polydatin in respiratory diseases: multi-target mechanisms and therapeutic potential.Frontiers in pharmacology · 2026Review
- Epidemiological burden and mortality of idiopathic pulmonary fibrosis in Brazil: historical trends and future outlook.Journal of thoracic disease · 2025Article
- Machine learning model development and validation using SHAP: predicting 28-day mortality risk in pulmonary fibrosis patients.BMC medical informatics and decision making · 2025Article
- Global epidemiology and burden of interstitial lung disease.The Lancet. Respiratory medicine · 2025Review
- The Relationship Between Chest Wall Muscle Thickness, Pulmonary Function, and Prognostic Markers in Idiopathic Pulmonary Fibrosis.Medicina (Kaunas, Lithuania) · 2025Article
- The role of lung cancer in mortality rate in chronic fibrosing idiopathic interstitial pneumonia.Scientific reports · 2025Article
- Incidence and survival of interstitial lung diseases in the UK in 2010-2019.ERJ open research · 2025Article
- Article
- Drug-Induced Pulmonary Fibrosis: National Database Analysis.Biomedicines · 2024Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious research has suggested that the incidence of idiopathic pulmonary fibrosis (IPF) is increasing in the UK and elsewhere. The aim of this study is to provide contemporary estimates of IPF mortality rates across 24 European Union (EU) countries from 2013 to 2018, using death certificate data from the European Statistics Institution (EUROSTAT) database.
methodsWe extracted country data for IPF (International Classification of Diseases, 10th Revision: code J84.1) mortality from the EUROSTAT dataset. We calculated country-, age- and sex-specific death registration rates between 2013 and 2018. We used direct standardisation to compare rates between countries. We calculated annual trends in mortality rate ratios using a segmented regression model.
resultsThe overall standardised mortality rate in 24 EU countries during this period was 3.90 (95% CI 3.80-3.90) per 100 000 person-years, with the rate rising from 3.70 in 2013 to 4.00 in 2018 (average annual percent change 1.74%, 95% CI 0.91-2.59%). We observed substantial inter-country differences, with the highest rates detected in Ireland, the UK and Finland, the lowest rate in Bulgaria, and middle rates in Germany, Greece, Italy, the Netherlands, Portugal and Slovenia.
conclusionsThe IPF mortality rate is increasing across Europe. There are currently more than 17 000 deaths recorded from IPF each year in Europe but the marked geographical differences we observed suggest that this figure may underestimate the true rate considerably.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.